Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Barbexaclone** is an oral barbiturate antiseizure drug consisting of a defined 1:1 salt of phenobarbital and levopropylhexedrine. Its antiseizure activity is principally attributable to the phenobarbital component, which enhances inhibitory gamma-aminobutyric acid type A receptor signaling and suppresses neuronal excitability. The levopropylhexedrine component is an indirect sympathomimetic stimulant intended to mitigate phenobarbital-associated sedation. Barbexaclone has been marketed as **Maliasin** and is available in Italy as barbesaclone film-coated tablets for epilepsy, including generalized tonic-clonic seizures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on barbexaclone (Knoll).